Home/ Stocks/ RPRX

Royalty Pharma plc Class A Ordinary Shares

RPRX XNAS

$50.79 +0.59 (+1.18%) ▲ 15-min delayed

Open

$50.78

High

$51.17

Low

$50.50

Volume

3.76M

Market Cap

$22.51B

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 100 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$630.58M	$468.26M	$0.67
FY 2025	$2.38B	$1.32B	$1.79
Q3 2025	$609.29M	$444.21M	$0.67
Q2 2025	$578.66M	$90.64M	$0.07

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for RPRX yet. Check out our latest market news or earnings calendar.

Get RPRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Royalty Pharma plc Class A Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.